Corcept Therapeutics (CORT)
72.35
-0.37 (-0.51%)
At close: Feb 18, 2025, 3:59 PM
72.60
0.35%
After-hours: Feb 18, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 69.13 |
| Market Cap | 7.58B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.26 |
| PE Ratio (ttm) | 57.42 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 76 |
| Volume | 390,358 |
| Avg. Volume (20D) | 834,922 |
| Open | 73.99 |
| Previous Close | 72.72 |
| Day's Range | 71.51 - 74.50 |
| 52-Week Range | 20.84 - 74.61 |
| Beta | undefined |
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 14, 2004
Employees 352
Stock Exchange NASDAQ
Ticker Symbol CORT
Website https://www.corcept.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $95.5, which is an increase of 32.00% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Corcept Therapeutics is scheduled to release its earnings on Feb 26, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+13.6%
Corcept Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
2 months ago
-6.24%
Corcept Therapeutics shares are trading lower after the company announced results from its Phase 2 DAZALS study evaluating two doses of dazucorilant in patients with ALS did not meet its primary endpoint.
